ClinicalTrials.gg
CompletedNCT02614794HER2CLIMBUpdated Aug 14, 2023Results posted

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

A Phase 2 interventional study of tucatinib and capecitabine in HER2 Positive Breast Cancer, sponsored by Seagen Inc.. Completed at 176 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing tucatinib in Breast Neoplasms — 7 open to participants now, 19 under way, 3 of them phase 3. tucatinib · Breast Neoplasms.

Enrollment
4th of 31
612 · median 41
Started
2016
the only one that year
Phase 2
16 of 31
6 open now
Registered
5th of 31
by date
Lead sponsor
3 of 31
Seagen Inc.

Among the 31 studies testing tucatinib in Breast Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 16 in phase 2, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 31 studies testing tucatinib in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tucatinib

tucatinib: first FDA approval 2020 (TUKYSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing tucatinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is being done to see if tucatinib works better than placebo to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. All patients in the study will get capecitabine and trastuzumab, two drugs that are often used to treat this cancer.

There are two parts to this study. The first part of the study is already complete. Patients were randomly assigned to get either tucatinib or placebo (a pill with no medicine). Since this part was "blinded," neither patients nor their doctors knew whether a patient got tucatinib or placebo.

The second part of the study is called the Unblinded Phase. In this part of the study, participants and their doctors know which drugs are being given. Participants who used to get or are currently getting placebo may be able to start taking tucatinib instead.

Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills two times every day. They will swallow capecitabine pills two times a day during the first two weeks of each cycle. Patients will get trastuzumab injections from the study site staff on the first day of every cycle.

Read the detailed description

This is a randomized, international, multi-center study in patients with progressive unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, pertuzumab and T-DM1. There are two phases to this trial: the Double-blind Phase and the Unblinded Phase. In the Double-blind phase, participants were randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. In the Unblinded Phase, patients on placebo may be offered tucatinib.

Stratification factors include presence or history of treated or untreated brain metastases or brain lesions of equivocal significance (yes/no), Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), and region of world (US vs. Canada vs. Rest of World).

Safety assessments will be performed at a minimum of once every three weeks throughout study treatment and 30 days after the last dose of study drugs. Laboratory assessments will be performed locally at sites. Left ventricular ejection fraction will be assessed by MUGA or ECHO at screening and once every 12 weeks thereafter.

For the blinded phase, contrast brain MRI was performed at baseline. Efficacy assessments (CT of chest, abdomen and pelvis at a minimum) utilized RECIST 1.1 and included patients with evaluable tumors defined as measurable target lesions and non-measurable non-target lesions. RECIST assessment was performed at baseline, every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter. Repeat MRI of the brain was required on this same schedule only in those patients with brain metastases identified at baseline. All treatment decisions were made based upon investigator assessment. All patients underwent a repeat MRI of the brain within 30 days of the end of treatment unless previously performed at time of disease progression.

For the unblinded phase, RECIST assessments will be performed per standard clinical practice as determined by investigator with a maximum interval of 12 weeks.

03

Conditions studied

  • HER2 Positive Breast Cancer

Keywords

  • Tucatinib
  • Capecitabine
  • Trastuzumab
  • Xeloda
  • Herceptin
  • Breast Cancer
  • ARRY-380
  • ONT-380
  • HER2 Positive Breast Carcinoma
  • HER2 Positive Locally Advanced Breast Cancer
  • HER-2 Positive Breast Cancer
  • HER-2 Positive Breast Carcinoma
  • HER-2 Positive Locally Advanced Breast Cancer
  • Recurrent Breast Carcinoma
  • Stage IV Breast Cancer
  • Metastatic Breast Cancer
  • Breast Carcinoma
  • Metastatic Malignant Neoplasm in the Brain
  • Brain Metastases in Breast Cancer
  • Asymptomatic Brain Metastases in Breast Cancer
  • Low Symptomatic Brain Metastases in Breast Cancer
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Double-blind Phase Inclusion Criteria

  • confirmed + breast carcinoma, with HER2+ defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology
  • Received previous treatment with trastuzumab, pertuzumab, and T-DM1
  • Progression of unresectable locally advanced or breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy
  • Have measurable or non- assessable by 1.1
  • (ECOG) Performance Status of 0 or 1
  • Adequate hepatic and renal function and hematologic parameters
  • (LVEF) ≥ 50%
  • CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:

    1. No evidence of
    2. Untreated brain metastases not needing immediate local therapy
    3. Previously treated brain metastases not needing immediate local therapy

      1. Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy
      2. Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if the following criteria are met:

      i. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days prior to first dose of study treatment, or time since surgical resection is ≥ 28 days.

      ii. Other sites of disease assessable by RECIST 1.1 are present

    4. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions

Double-blind Phase Exclusion Criteria

  • Previously been treated with:

    1. lapatinib within 12 months of starting study treatment (except in cases where lapatinib was given for ≤ 21 days and was discontinued for reasons other than disease progression or toxicity)
    2. neratinib, afatinib, or other HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously
    3. capecitabine (or other fluoropyrimidine) for metastatic disease except in cases where capecitabine was given for \< 21 days and was discontinued for reasons other than disease progression or toxicity. Patients who have received capecitabine for or neoadjuvant treatment at least 12 months prior to starting study treatment are eligible.
  • cardiopulmonary disease
  • Carriers of or or have other known chronic liver disease
  • Positive for (HIV)
  • Unable for any reason to undergo MRI of the brain
  • Have used a strong or CYP2C8 inhibitor within 5 half-lives of the inhibitor, or a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment
  • Have known dihydropyrimidine dehydrogenase deficiency (DPD)
  • CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:

    1. Any untreated brain lesions > 2.0 cm in size, unless approved by medical monitor
    2. Ongoing use of systemic for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
    3. Any brain lesion thought to require immediate local therapy. Patients who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under CNS inclusion criteria
    4. Known or suspected (LMD)
    5. Poorly controlled seizures Unblinded Phase Crossover Inclusion Criteria - Participants who were randomized to the control arm (placebo + trastuzumab + capecitabine) must meet the following criteria to be eligible to crossover to the experimental arm.
  • Have measurable or non-measurable disease assessable by RECIST 1.1
  • For patients who were randomized to the control arm and on the long-term follow-up period at the time of crossover screening: have progression of unresectable locally advanced or metastatic breast cancer after last systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy.
  • Have an ECOG Performance Status of 0 or 1
  • Have a of at least 6 months
  • Have adequate hepatic and renal function and hematologic parameters
  • Left ventricular ejection fraction (LVEF) ≥ 50%
  • CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have one of the following:

    i. No evidence of brain metastases ii. Untreated brain metastases not needing immediate local therapy iii. Previously treated brain metastases not needing immediate local therapy

  • Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy
  • Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if the following criteria are met:

    1. Time since whole brain radiation therapy (WBRT) is ≥ 21 days prior to first dose of study treatment, time since stereotactic radiosurgery (SRS) is ≥ 7 days prior to first dose of study treatment, or time since surgical resection is ≥ 28 days.
    2. Other sites of disease assessable by RECIST 1.1 are present Unblinded Phase Crossover Exclusion Criteria - Participants who were randomized to the control arm (placebo + trastuzumab + capecitabine) will be excluded from the crossover to the experimental arm for any of the following reasons.
  • Discontinuation of study treatment due to an adverse event while on the double-blind phase of the study. If the adverse event leading to discontinuation of study treatment has resolved, the patient may be allowed to crossover with approval from the medical monitor.
  • History of exposure to the following cumulative doses of anthracyclines:

    • Doxorubicin > 360 mg/m\^2
    • Epirubicin > 720 mg/m\^2
    • Mitoxantrone > 120 mg/m\^2
    • Idarubicin > 90 mg/m\^2
    • Liposomal doxorubicin > 550 mg/m\^2
  • History of allergic reactions to trastuzumab, capecitabine, or compounds chemically or biologically similar to tucatinib

    o Exceptions for Grade 1 or 2 infusion related reactions to trastuzumab that were successfully managed, or known allergy to one of the in the study drugs

  • Have received treatment with any systemic anti-cancer therapy, non-CNS radiation, or experimental agent within 3 weeks prior to start of crossover therapy
  • Any toxicity related to prior cancer therapies that has not resolved to ≤ Grade 1, with the following exceptions:

    • Alopecia and neuropathy (must have resolved to ≤ Grade 2)
    • CHF (must have been ≤ Grade 1 in severity at the time of occurrence and must have resolved completely)
    • Anemia (must have resolved to ≤ Grade 2)
  • Have clinically significant cardiopulmonary disease
  • Have known myocardial infarction or unstable angina within 6 months prior to start of crossover therapy
  • Require therapy with warfarin or other coumarin derivatives
  • Inability to swallow pills or significant gastrointestinal disease which would preclude the adequate oral absorption of medications
  • Have used a strong CYP2C8 inhibitor within 5 half-lives of the inhibitor or have used a strong CYP2C8 or CYP34A inducer within 5 days prior to start of the crossover (tucatinib) treatment.
  • Known dihydropyrimidine dehydrogenase deficiency
  • Unable to undergo contract MRI of the brain
  • Have evidence within 2 years prior to start of crossover therapy of another that required systemic treatment
  • CNS Exclusion:
  • CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:

    • Any untreated brain lesions > 2.0 cm in size, unless approved by medical monitor
    • Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
    • Any brain lesion thought to require immediate local therapy. Patients who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under CNS inclusion criteria
    • Known or suspected leptomeningeal disease (LMD)
    • Poorly controlled seizures
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
612 participants (actual)

Study arms

  • Experimental
    Tucatinib in combination with capecitabine & trastuzumab

    Tucatinib + capecitabine + trastuzumab

    Drug: tucatinib · Drug: capecitabine · Drug: trastuzumab

  • Active comparator
    Placebo in combination with capecitabine & trastuzumab

    Placebo + capecitabine + trastuzumab

    Drug: capecitabine · Drug: trastuzumab · Drug: placebo

Interventions

  • 300 mg orally twice daily

    Also known as: ONT-380, ARRY-380

  • 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle

    Also known as: Xeloda

  • 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.

    Also known as: Herceptin, Herceptin Hycleta

  • Drugplacebo

    Oral dose twice daily

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)

    Defined as the time from the date of randomization to the date of documented disease progression.

    Time frame: 34.6 months

Secondary outcomes

  1. PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR

    Defined as the time from the date of randomization to the date of documented disease progression.

    Time frame: 34.6 months

  2. Overall Survival (OS) at Time of Primary Analysis

    Defined as time from randomization to death from any cause

    Time frame: 35.9 months

  3. Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR

    Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: 34.6 months

  4. ORR Per RECIST 1.1 as Determined by Investigator Assessment

    Defined as achieving a best overall response of confirmed CR or confirmed PR.

    Time frame: 34.6 months

  5. PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis

    Defined as the time from the date of randomization to the date of documented disease progression

    Time frame: 34.6 months

  6. Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR

    Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.

    Time frame: 24.6 months

  7. DOR Per RECIST 1.1 as Determined by Investigator Assessment

    Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.

    Time frame: 33.2 months

  8. Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1

    Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).

    Time frame: 34.6 months

  9. CBR Per RECIST 1.1 as Determined by Investigator Assessment

    Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.

    Time frame: 34.6 months

  10. Incidence of Adverse Events (AEs) at Time of Primary Analysis

    As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.

    Time frame: 36.1 months

  11. Frequency of Dose Modifications

    Time frame: 35.1 months

  12. Incidence of Health Resources Utilization

    Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.

    Time frame: 36.1 months

  13. Pharmacokinetic Measure: Ctrough of Tucatinib

    Individual plasma tucatinib concentrations at each sampling time

    Time frame: 3.5 months

  14. Pharmacokinetic Measure: ONT-993

    Individual plasma primary metabolite concentrations at each sampling time

    Time frame: 3.5 months

  15. Overall Survival (OS) at Time of Final Analysis

    Defined as time from randomization to death from any cause

    Time frame: Up to 60.1 months

  16. PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis

    Defined as the time from the date of randomization to the date of documented disease progression

    Time frame: Up to 58.0 months

  17. Incidence of Adverse Events (AEs) at Time of Final Analysis

    As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.

    Time frame: Up to 60.1 months

  18. Frequency of Dose Modifications at Time of Final Analysis

    Time frame: Up to 60.1 months

07

Results

Posted Sep 28, 2020

Participant flow

Participant flow — Overall Study
MilestoneTuc+Cap+TraPbo+Cap+Tra
Started410202
Completed00
Not completed410202
Withdrew: Death258151
Withdrew: Study closure by sponsor11945
Withdrew: Withdrawal by subject245
Withdrew: Lost to follow-up70
Withdrew: Physician decision11
Withdrew: Hospital closure10

Outcome measures

PrimaryProgression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)

Defined as the time from the date of randomization to the date of documented disease progression.

Time frame:
34.6 months
Reported as:
Median · months
Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)
monthsTuc+Cap+TraPbo+Cap+Tra
Progression-free Survival (PFS) Per RECIST 1.1 as Determined by Blinded Independent Central Review (BICR)7.8 (4.3 to 17.8)5.6 (3.0 to 9.7)
SecondaryPFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR

Defined as the time from the date of randomization to the date of documented disease progression.

Time frame:
34.6 months
Reported as:
Median · months
PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR
monthsTuc+Cap+TraPbo+Cap+Tra
PFS in Patients With Brain Metastases at Baseline Using RECIST 1.1 as Determined by BICR7.6 (4.2 to 11.8)5.4 (3.0 to 7.5)
SecondaryOverall Survival (OS) at Time of Primary Analysis

Defined as time from randomization to death from any cause

Time frame:
35.9 months
Reported as:
Median · months
Overall Survival (OS) at Time of Primary Analysis
monthsTuc+Cap+TraPbo+Cap+Tra
Overall Survival (OS) at Time of Primary Analysis21.9 (18.3 to 31.0)17.4 (13.6 to 19.9)
SecondaryConfirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR

Defined as achieving a best overall response of confirmed complete response (CR) or confirmed partial response (PR).

Time frame:
34.6 months
Reported as:
Number · percentage of participants
Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR
percentage of participantsTuc+Cap+TraPbo+Cap+Tra
Confirmed Objective Response Rate (ORR) Per RECIST 1.1 as Determined by BICR40.7 (34.8 to 46.7)23.4 (16.6 to 31.3)
SecondaryORR Per RECIST 1.1 as Determined by Investigator Assessment

Defined as achieving a best overall response of confirmed CR or confirmed PR.

Time frame:
34.6 months
Reported as:
Number · percentage of participants
ORR Per RECIST 1.1 as Determined by Investigator Assessment
percentage of participantsTuc+Cap+TraPbo+Cap+Tra
ORR Per RECIST 1.1 as Determined by Investigator Assessment41.4 (35.6 to 47.4)23.0 (16.3 to 30.9)
SecondaryPFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis

Defined as the time from the date of randomization to the date of documented disease progression

Time frame:
34.6 months
Reported as:
Median · months
PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis
monthsTuc+Cap+TraPbo+Cap+Tra
PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Primary Analysis7.5 (4.1 to 13.1)4.3 (2.7 to 8.4)
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Determined by BICR

Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.

Time frame:
24.6 months
Reported as:
Median · months
Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR
monthsTuc+Cap+TraPbo+Cap+Tra
Duration of Response (DOR) Per RECIST 1.1 as Determined by BICR8.3 (4.3 to 12.8)6.3 (4.2 to 9.0)
SecondaryDOR Per RECIST 1.1 as Determined by Investigator Assessment

Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.

Time frame:
33.2 months
Reported as:
Median · months
DOR Per RECIST 1.1 as Determined by Investigator Assessment
monthsTuc+Cap+TraPbo+Cap+Tra
DOR Per RECIST 1.1 as Determined by Investigator Assessment7.0 (4.3 to 12.9)6.9 (4.1 to 9.6)
SecondaryClinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1

Clinical benefit was defined as achieving stable disease (SD) or non-complete response (CR)/non-progressive disease (PD) for at least 6 months or a best overall response of confirmed CR or confirmed partial response (PR).

Time frame:
34.6 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.1
percentage of participantsTuc+Cap+TraPbo+Cap+Tra
Clinical Benefit Rate (CBR) as Determined by BICR Per RECIST 1.159.8 (54.8 to 64.5)38.1 (31.4 to 45.2)
SecondaryCBR Per RECIST 1.1 as Determined by Investigator Assessment

Clinical benefit was defined as achieving stable disease (SD) or non-CR/non-PD for at least 6 months or a best overall response of confirmed CR or confirmed PR.

Time frame:
34.6 months
Reported as:
Number · percentage of participants
CBR Per RECIST 1.1 as Determined by Investigator Assessment
percentage of participantsTuc+Cap+TraPbo+Cap+Tra
CBR Per RECIST 1.1 as Determined by Investigator Assessment58.0 (53.1 to 62.9)37.6 (30.9 to 44.7)
SecondaryIncidence of Adverse Events (AEs) at Time of Primary Analysis

As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.

Time frame:
36.1 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs) at Time of Primary Analysis
ParticipantsTuc+Cap+TraPbo+Cap+Tra
Any treatment-emergent AE (TEAE)401191
Any Grade 3 or higher TEAE22396
Any treatment-emergent serious AE10453
TEAE leading to death86
SecondaryFrequency of Dose Modifications
Time frame:
35.1 months
Reported as:
Count of participants · Participants
Frequency of Dose Modifications
ParticipantsTuc+Cap+TraPbo+Cap+Tra
TEAEs resulting in tuc/pbo dose modification22081
TEAEs resulting in tucatinib/placebo dose hold21680
TEAEs resulting in tuc/pbo dose reduction8421
TEAEs resulting capecitabine dose modification313122
TEAEs resulting in capecitabine dose hold276113
TEAEs resulting in capecitabine dose reduction24377
TEAEs resulting trastuzumab dose modification10438
TEAEs resulting in trastuzumab dose hold10438
SecondaryIncidence of Health Resources Utilization

Cumulative incidence of health resource utilization, including length of stay, hospitalizations, and ER visits using the EQ-5D-5L questionnaire.

Time frame:
36.1 months
Reported as:
Number · hospitalizations
Incidence of Health Resources Utilization
hospitalizationsTuc+Cap+TraPbo+Cap+Tra
Total number of hospitalizations14375
Hospitalization for AE12464
Planned hospitalization (other than AE)106
Ambulatory Surgery30
Other65
SecondaryPharmacokinetic Measure: Ctrough of Tucatinib

Individual plasma tucatinib concentrations at each sampling time

Time frame:
3.5 months
Reported as:
Mean · ng/mL
Pharmacokinetic Measure: Ctrough of Tucatinib
ng/mLTuc+Cap+Tra
Cycle 2, Day 1 (Pre-dose)246.1 ± 260.9
Cycle 3, Day 1 (Pre-dose)227.6 ± 210.8
Cycle 3, Day 1 (Post-dose)507.1 ± 357.1
Cycle 4, Day 1 (Pre-dose)253.2 ± 236.1
Cycle 5, Day 1 (Pre-dose)257.6 ± 286.9
Cycle 6, Day 1 (Pre-dose)247.8 ± 225.1
SecondaryPharmacokinetic Measure: ONT-993

Individual plasma primary metabolite concentrations at each sampling time

Time frame:
3.5 months
Reported as:
Mean · ng/mL
Pharmacokinetic Measure: ONT-993
ng/mLTuc+Cap+Tra
Cycle 2, Day 1 (Pre-dose)25.5 ± 24.4
Cycle 3, Day 1 (Pre-dose)22.6 ± 20.6
Cycle 3, Day 1 (Post-dose)47.7 ± 47.2
Cycle 4, Day 1 (Pre-dose)25.2 ± 24.3
Cycle 5, Day 1 (Pre-dose)24.5 ± 30.6
Cycle 6, Day 1 (Pre-dose)20.9 ± 18.0
SecondaryOverall Survival (OS) at Time of Final Analysis

Defined as time from randomization to death from any cause

Time frame:
Up to 60.1 months
Reported as:
Median · months
Overall Survival (OS) at Time of Final Analysis
monthsTuc+Cap+TraPbo+Cap+Tra
Overall Survival (OS) at Time of Final Analysis24.7 (21.6 to 28.9)19.2 (16.4 to 21.4)
SecondaryPFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis

Defined as the time from the date of randomization to the date of documented disease progression

Time frame:
Up to 58.0 months
Reported as:
Median · months
PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis
monthsTuc+Cap+TraPbo+Cap+Tra
PFS Per RECIST 1.1 as Determined by Investigator Assessment at Time of Final Analysis7.6 (4.1 to 13.8)4.9 (2.7 to 9.0)
SecondaryIncidence of Adverse Events (AEs) at Time of Final Analysis

As determined by assessment of AEs, clinical laboratory tests, and vital signs measurements. AEs were classified by system organ class (SOC) and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) Version 22.0 or higher; AE severities were classified using Version 4.03 of the (Common Terminology Criteria for Adverse Events) CTCAE criteria.

Time frame:
Up to 60.1 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs) at Time of Final Analysis
ParticipantsTuc+Cap+TraPbo+Cap+Tra
Any treatment-emergent AE (TEAE)401191
Any Grade 3 or higher TEAE248101
Any treatment-emergent serious AE12358
TEAE leading to death86
SecondaryFrequency of Dose Modifications at Time of Final Analysis
Time frame:
Up to 60.1 months
Reported as:
Count of participants · Participants
Frequency of Dose Modifications at Time of Final Analysis
ParticipantsTuc+Cap+TraPbo+Cap+Tra
TEAEs resulting in tuc/pbo dose modification23785
TEAEs resulting in tucatinib/placebo dose hold23284
TEAEs resulting in tuc/pbo dose reduction9221
TEAEs resulting capecitabine dose modification322125
TEAEs resulting in capecitabine dose hold288117
TEAEs resulting in capecitabine dose reduction25179
TEAEs resulting trastuzumab dose modification11741
TEAEs resulting in trastuzumab dose hold11741

Adverse events

Collected over Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 60.1 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tuc+Cap+Tra262/410 (63.9%)124/404 (30.7%)399/404 (98.8%)
Pbo+Cap+Tra152/202 (75.2%)62/197 (31.5%)188/197 (95.4%)
Most frequent serious events
Showing 10 of 157
Most frequent serious events
EventTuc+Cap+TraPbo+Cap+Tra
DiarrhoeaGastrointestinal disorders17/4047/197
DyspnoeaRespiratory, thoracic and mediastinal disorders6/4047/197
Pleural effusionRespiratory, thoracic and mediastinal disorders3/4046/197
VomitingGastrointestinal disorders11/4045/197
SeizureNervous system disorders11/4042/197
NauseaGastrointestinal disorders9/4044/197
HypokalaemiaMetabolism and nutrition disorders1/4044/197
PneumoniaInfections and infestations8/4043/197
Ejection fraction decreasedInvestigations6/4043/197
HeadacheNervous system disorders2/4043/197
Most frequent other events
Showing 10 of 66
Most frequent other events
EventTuc+Cap+TraPbo+Cap+Tra
DiarrhoeaGastrointestinal disorders330/404106/197
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders265/404105/197
NauseaGastrointestinal disorders243/40487/197
FatigueGeneral disorders193/40487/197
VomitingGastrointestinal disorders155/40449/197
Decreased appetiteMetabolism and nutrition disorders108/40441/197
StomatitisGastrointestinal disorders105/40428/197
HeadacheNervous system disorders98/40438/197
Aspartate aminotransferase increasedInvestigations92/40423/197
AnaemiaBlood and lymphatic system disorders89/40424/197

Baseline characteristics

Intent-to-treat Overall Survival (ITT-OS) Population: Includes all randomized participants evaluated by their randomized treatment assignment.

Age, Categorical
Age, Categorical(Participants)Tuc+Cap+TraPbo+Cap+TraTotal
<=18 years000
Between 18 and 65 years328168496
>=65 years8234116
Age, Continuous
Age, Continuous(years)Tuc+Cap+TraPbo+Cap+TraTotal
Median55 (22 to 80)54 (25 to 82)54 (22 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Tuc+Cap+TraPbo+Cap+TraTotal
Female407200607
Male325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tuc+Cap+TraPbo+Cap+TraTotal
Hispanic or Latino371451
Not Hispanic or Latino362184546
Unknown or Not Reported11415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tuc+Cap+TraPbo+Cap+TraTotal
American Indian or Alaska Native000
Asian18523
Native Hawaiian or Other Pacific Islander000
Black or African American411455
White287157444
More than one race000
Unknown or Not Reported642690
Region of Enrollment
Region of Enrollment(Participants)Tuc+Cap+TraPbo+Cap+TraTotal
United States220111331
France291746
United Kingdom331245
Australia271239
Canada261238
Spain19726
Denmark13720
Germany9817
Israel13316
Belgium4610
Italy639
Austria617
Portugal314
Czech Republic213
Switzerland011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Tuc+Cap+TraPbo+Cap+TraTotal
0: Normal activity20494298
1: Symptoms, but ambulatory206108314
08

Study locations

176 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • University of South Alabama - Mitchell Cancer Institute
    Mobile, Alabama 36604, United States
  • Cancer Treatment Centers of America - Phoenix
    Goodyear, Arizona 85338, United States
  • Arizona Oncology Associates, PC - HAL
    Phoenix, Arizona 85016, United States
  • City of Hope National Medical Center
    Duarte, California 91010-3000, United States
  • TRIO - Central Regulatory Office
    Los Angeles, California 90095, United States
  • UCLA Medical Center / David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • Torrance Memorial Physician Network - TRIO
    Redondo Beach, California 90277, United States
  • University of California at San Francisco
    San Francisco, California 94134, United States
  • Kaiser Permanente San Marcos Medical Offices
    San Marcos, California 92078, United States
  • Central Coast Medical Oncology Corporation TRIO
    Santa Maria, California 93454, United States
  • Kaiser Permanente Medical Center Northern California
    Vallejo, California 94589, United States
  • University of Colorado Hospital / University of Colorado
    Aurora, Colorado 80045-0510, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Lombardi Cancer Center / Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists - South Region
    Fort Myers, Florida 33901, United States
  • Memorial Regional Hospital TRIO
    Hollywood, Florida 33021, United States
  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida 32207, United States
  • Mount Sinai Medical Center / Florida
    Miami Beach, Florida 33140, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Orlando Health, Inc. TRIO
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists - North Region
    Saint Petersburg, Florida 33705, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Florida Cancer Specialists - East West Palm Beach, FL (SCRI)
    West Palm Beach, Florida 33401, United States
  • Winship Cancer Institute / Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Cancer Treatment Centers of America
    Newnan, Georgia 30265, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637-1470, United States
  • Illinois Cancer Specialists / Advocate Lutheran General Hospital
    Niles, Illinois 60714, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Maryland Oncology Hematology, P.A.
    Rockville, Maryland 20850, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • Saint Luke's Cancer Institute LLC
    Kansas City, Missouri 64113, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Dartmouth-Hitchcock Medical Center/ Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Mount Sinai Beth Israel
    New York, New York 10003, United States
  • New York University (NYU) Cancer Institute
    New York, New York 10016, United States
  • Stony Brook University Cancer Center
    Stony Brook, New York 11794, United States
  • UNC Lineberger Comprehensive Cancer Center / University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Leo W. Jenkins Cancer Services / Brody School of Medicine East Carolina University
    Greenville, North Carolina 27834, United States
  • James Cancer Hospital / Ohio State University
    Columbus, Ohio 43210, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Oregon Health and Science University
    Portland, Oregon 97239-3098, United States
  • Northwest Cancer Specialists, P.C.
    Tualatin, Oregon 97062, United States
  • University of Pennsylvania / Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Cancer Treatment Centers of America / Eastern Regional Medical Center
    Philadelphia, Pennsylvania 19124, United States
  • Roper St. Francis Healthcare
    Charleston, South Carolina 29414, United States
  • Medical University of South Carolina/Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Wellmont Cancer Institute
    Kingsport, Tennessee 37660, United States
  • Tennessee Oncology - Nashville
    Nashville, Tennessee 37203, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705, United States
  • Texas Oncology Methodist
    Dallas, Texas 75203, United States
  • Texas Oncology - Denton South
    Denton, Texas 76210, United States
  • The Center for Cancer and Blood Disorders: Fortworth
    Fort Worth, Texas 76104, United States
  • Texas Oncology - Houston Memorial City
    Houston, Texas 77024, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4095, United States
  • Baylor Clinic
    Houston, Texas 77030, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Paris Regional Medical Center / US Oncology
    Paris, Texas 75460, United States
  • Texas Oncology - Plano East
    Plano, Texas 75075, United States
  • Texas Oncology - San Antonio Medical Center Northeast
    San Antonio, Texas 78212, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • US Oncology Central Regulatory
    The Woodlands, Texas 77380, United States
  • Texas Oncology - Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Shenandoah Oncology P.C.
    Winchester, Virginia 22601, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
  • Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98109-1023, United States
  • Carbone Cancer Center / University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Austin Hospital
    Heidelberg, 3084, Australia
  • Cabrini Education and Research Precinct
    Malvern, 3144, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, 3000, Australia
  • Breast Cancer Research Centre
    Nedlands, 6009, Australia
  • Mater Hospital
    North Sydney, 2060, Australia
  • Icon Cancer Care South Brisbane
    South Brisbane, 4101, Australia
  • Mater Health Services
    South Brisbane, 4101, Australia
  • Sunshine Hospital
    St Albans, 3021, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • LKH- Universitat Klinikum Graz
    Graz, 8036, Austria
  • Medizinische Universitat Innsbruck
    Innsbruck, 6020, Austria
  • KH d. Barmherzigen Schwestern Linz
    Linz, 4010, Austria
  • LKH Salzburg, Universitatsklinikum der PMU
    Salzburg, 5020, Austria
  • AZ Klina
    Brasschaat, 2930, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Centre Hospitalier de l'Ardenne
    Libramont, 6800, Belgium
  • CHU UCL Namur-Site de Saint Elisabeth
    Namur, 5000, Belgium
  • Tom Baker Cancer Centre
    Calgary, T2N 4N2, Canada

Showing the first 100 of 176 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mueller V, Wardley A, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Harder Brix E, Brenner A, Crouzet L, Ferrario C, Munoz-Mateu M, Arkenau HT, Iqbal N, Aithal S, Block M, Cold S, Cancel M, Hahn O, Poosarla T, Stringer-Reasor E, Colleoni M, Cameron D, Curigliano G, Siadak M, DeBusk K, Ramos J, Feng W, Gelmon K. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer. 2021 Aug;153:223-233. doi: 10.1016/j.ejca.2021.05.025. Epub 2021 Jun 29. PubMed 34214937 ↗
  • Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29. PubMed 32468955 ↗
  • Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. Erratum In: N Engl J Med. 2020 Feb 6;382(6):586. doi: 10.1056/NEJMx190039. PubMed 31825569 ↗
  • Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 Jul;19(7):880-888. doi: 10.1016/S1470-2045(18)30256-0. Epub 2018 May 24. PubMed 29804905 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Sep 2019, 43 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 43 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2015
First posted
Nov 25, 2015
StartActual
Jan 28, 2016
Primary completionActual
Sep 4, 2019
CompletionActual
Aug 11, 2022
Results first posted
Sep 28, 2020
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02614794
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Nov 25, 2015
Start date
Jan 28, 2016
Primary completion
Sep 4, 2019
Completion
Aug 11, 2022
Results posted
Sep 28, 2020
Last update
Aug 14, 2023

Study contacts

Jorge Ramos, DO
study director · Seagen Inc.
Corinna Palanca-Wessels, MD, PhD
study director · Seagen Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion